Trial Profile
Belatacept and Risk of PTLD in US Renal Transplant Recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2022
Price :
$35
*
At a glance
- Drugs Belatacept (Primary) ; Calcineurin inhibitors
- Indications Renal transplant rejection
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 20 Jul 2022 Status changed from active, no longer recruiting to completed.
- 03 Jun 2020 Results (n=1737) assessing patterns of belatacept use and incidence of PTLD in kidney transplant recipients in clinical practice using data from OPTN database(UNOS) from two clinical studies (NCT01656343 and a US-based observational study) presented at the 2020 American Transplant Congress
- 26 Mar 2018 Planned End Date changed from 30 Jun 2018 to 30 Jun 2019.